Breast Cancer Anti-Estrogen Resistance Protein 1 (BCAR1) Antibody

Este producto es parte de BCAR scaffold protein, Cas family member
Product Graph
364€ (100 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Breast Cancer Anti-Estrogen Resistance Protein 1 (BCAR1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx010317
tested applications
ELISA, WB

Description

Breast Cancer Anti-Estrogen Resistance Protein 1 (BCAR1) Antibody is a Rabbit Polyclonal antibody for the detection of BCAR1.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Breast Cancer Anti-Estrogen Resistance Protein 1 (BCAR1)
Host
Rabbit
Reactivity
Human, Mouse, Rat
Recommended Dilution
WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purity
≥ 95% (SDS-PAGE)
Purification
Purified by immunogen affinity chromatography.
Size 1
100 µg
Form
Liquid
Tested Applications
ELISA, WB
Buffer
PBS, pH 7.3, with 0.02% sodium azide and 50% glycerol.
Availability
Shipped within 5-12 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P56945
Gene ID
9564
OMIM
602941
Alias
BCAR1, CAS, CAS1, CASS1, CRKAS, P130Cas, Cas family scaffolding protein, Cas family scaffold protein, BCAR1 scaffold protein, Cas family member
Background
Antibody anti-BCAR1
Status
RUO
Note
Concentration: 2 mg/ml - Validity: 12 months.

Descripción

BCAR1, also known as the Breast Cancer Anti-Estrogen Resistance 1 protein, is an important protein involved in the development of resistance to anti-estrogen therapies, such as tamoxifen, used in the treatment of estrogen receptor-positive breast cancer. BCAR1 plays a crucial role in cell signaling pathways that regulate cell survival, proliferation, and resistance to apoptosis. It is often upregulated in breast cancer cells that become resistant to estrogen receptor-targeted therapies. The protein interacts with several other signaling molecules involved in the regulation of cell motility and survival, contributing to the metastatic potential of breast cancer cells. Understanding BCAR1’s role in therapy resistance has significant implications for developing alternative therapeutic strategies for patients with estrogen receptor-positive breast cancer who develop resistance to current treatments.

Related Products

EH2694

Human BCAR1 (Breast Cancer Anti Estrogen Resistance 1) ELISA Kit

Ver Producto
FNab06061

BCAR1 antibody

Ver Producto
FNab10802

BCAR1 antibody

Ver Producto